| Literature DB >> 25206473 |
Yongmei Yan1, Wentao Fan1, Li Liu2, Ru Yang3, Wenjia Yang3.
Abstract
The Xingnao Jieyu capsule has been shown to effectively relieve neurologic impairments and lessen depression. It remains poorly understood whether this capsule can be used to treat post-stroke depression. Thus, in the present study, we established a rat model of post-stroke depression using left middle cerebral artery occlusions in combination of chronic unpredictable stress and solitary housing during development. Experimental rats received intragastric perfusion with 0.82, 0.41, and 0.20 g/kg Xingnao Jieyu capsules separately dissolved in 2 mL distilled water. Fluoxetine served as a positive control. The treatment was conducted over 28 days. Sugar water consumption test, open-field test, real-time fluorescent quantitative PCR and immunohistochemical staining results demonstrated that intragastric perfusion with various doses of Xingnao Jieyu capsules increased sugar water consumption, voluntary behaviors and synaptotagmin mRNA and protein expression in rats with post-stroke depression. These therapeutic effects were similar to those of fluoxetine. These results indicate that Xingnao Jieyu capsules upregulate synaptotagmin expression in hippocampi of rats with post-stroke depression, and exert antidepressant effects.Entities:
Keywords: Xingnao Jieyu capsule; chronic stress; depression; grants-supported paper; hippocampus; neural regeneration; neurologic impairment; neuroregeneration; post-stroke depression; stroke; synapsin; traditional Chinese medicine
Year: 2013 PMID: 25206473 PMCID: PMC4145951 DOI: 10.3969/j.issn.1673-5374.2013.19.004
Source DB: PubMed Journal: Neural Regen Res ISSN: 1673-5374 Impact factor: 5.135
Figure 1Effects of the Xingnao Jieyu capsule on synaptotagmin expression in the hippocampal CA1 region of rats with post-stroke depression (immunohistochemical staining, optical microscope, × 20).
Compared with the model group (A), the number of synaptotagmin-positive cells (arrows) was significantly higher in the high-, moderate-, and low-dose Xingnao Jieyu capsule groups (D–F) and the fluoxetine group (C). No significant changes in the number of synaptotagmin-positive cells were visible in the blank control group (B). High-, moderate-, and low-dose Xingnao Jieyu capsule and fluoxetine groups: 0.82, 0.41, 0.20 g/kg Xingnao Jieyu capsule medicine powder and 2.08 g/kg fluoxetine medicine powder were dissolved in 2 mL distilled water for intragastric administration.
Effects of the Xingnao Jieyu capsule on synaptotagmin expression in the hippocampal CA1 region of rats with post-stroke depression
Effects of the Xingnao Jieyu capsule on synaptotagmin mRNA expression in the hippocampal CA1 region of rats with post-stroke depression
Effects of the Xingnao Jieyu capsule on sugar water consumption in rats with post-stroke depression (%)
Effects of the Xingnao Jieyu capsule on horizontal movement in rats with post-stroke depression (open-field test, number of movement/3 minutes)
Effects of the Xingnao Jieyu capsule on vertical movements in rats with post-stroke depression (open-field test, number of movements/3 minutes)